Treatment of leptomeningeal carcinomatosis: Current challenges and future opportunities
- 1 April 2015
- journal article
- review article
- Published by Elsevier in Journal of Clinical Neuroscience
- Vol. 22 (4), 632-637
- https://doi.org/10.1016/j.jocn.2014.10.022
Abstract
No abstract availableKeywords
This publication has 56 references indexed in Scilit:
- Selective Permeabilization of the Blood–Brain Barrier at Sites of MetastasisJNCI Journal of the National Cancer Institute, 2013
- Breast cancer leptomeningeal metastasis: propensity of breast cancer subtypes for leptomeninges and the analysis of factors influencing survivalMedical Oncology, 2013
- Lapatinib Distribution in HER2 Overexpressing Experimental Brain Metastases of Breast CancerPharmaceutical Research, 2011
- Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastasesJournal of Neuro-Oncology, 2011
- Complete response in HER2+ leptomeningeal carcinomatosis from breast cancer with intrathecal trastuzumabBreast Cancer Research and Treatment, 2011
- Survival of breast cancer patients with meningeal carcinomatosisAnnals of Oncology, 2010
- Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast CancerClinical Cancer Research, 2009
- Capecitabine Therapy of Central Nervous System Metastases from Breast CancerJournal of Neuro-Oncology, 2007
- Central nervous system metastases in women who receive trastuzumab‐based therapy for metastatic breast carcinomaCancer, 2003
- Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabineBritish Journal of Cancer, 2001